37.84
+0.54(+1.45%)
Currency In USD
| Previous Close | 37.3 |
| Open | 37.06 |
| Day High | 38.09 |
| Day Low | 36.76 |
| 52-Week High | 38.08 |
| 52-Week Low | 24.05 |
| Volume | 4.6M |
| Average Volume | 3.86M |
| Market Cap | 16.36B |
| PE | 16.31 |
| EPS | 2.32 |
| Moving Average 50 Days | 36.22 |
| Moving Average 200 Days | 34.35 |
| Change | 0.54 |
If you invested $1000 in Royalty Pharma plc (RPRX) since IPO date, it would be worth $937.79 as of November 05, 2025 at a share price of $37.84. Whereas If you bought $1000 worth of Royalty Pharma plc (RPRX) shares 3 years ago, it would be worth $948.85 as of November 05, 2025 at a share price of $37.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
GlobeNewswire Inc.
Yesterday at 12:15 PM GMT
NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by Blackstone Life Sciences (“Blackstone”) for $310
Royalty Pharma Declares Fourth Quarter 2025 Dividend
GlobeNewswire Inc.
Oct 17, 2025 12:15 PM GMT
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on December
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
GlobeNewswire Inc.
Oct 09, 2025 8:15 PM GMT
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025 before the U.S. financial markets open. The company will host